Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : UNII-38R1Q0L1ZE
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Telix Pharmaceuticals | National Cancer Institute | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2018
Lead Product(s) : UNII-38R1Q0L1ZE
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Telix Pharmaceuticals | National Cancer Institute | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : UNII-38R1Q0L1ZE
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Blue Earth Diagnostics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2017
Lead Product(s) : UNII-38R1Q0L1ZE
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Blue Earth Diagnostics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : UNII-38R1Q0L1ZE
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2010
Lead Product(s) : UNII-38R1Q0L1ZE
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable